• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

(1-methyl-1H-1,3-benzodiazol-2-yl)methanol (CAS No. 7467-35-8): An Overview of a Versatile Compound in Medicinal Chemistry

(1-methyl-1H-1,3-benzodiazol-2-yl)methanol (CAS No. 7467-35-8) is a compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential therapeutic applications. This compound belongs to the class of benzodiazepines, which are widely studied for their diverse biological activities, including anxiolytic, sedative, and anticonvulsant properties.

The chemical structure of (1-methyl-1H-1,3-benzodiazol-2-yl)methanol is characterized by a benzodiazepine core with a methanol substituent at the 2-position. This specific substitution imparts unique chemical and biological properties to the molecule, making it a valuable candidate for various pharmaceutical applications. The methanol group can participate in hydrogen bonding and other intermolecular interactions, which can influence the compound's solubility, stability, and bioavailability.

Recent research has highlighted the potential of (1-methyl-1H-1,3-benzodiazol-2-yl)methanol in the development of novel therapeutic agents. Studies have shown that this compound can modulate the activity of GABA receptors, which are key targets for treating anxiety disorders and epilepsy. The ability to fine-tune the interaction with these receptors through structural modifications has opened up new avenues for drug design and optimization.

In addition to its potential as a GABA receptor modulator, (1-methyl-1H-1,3-benzodiazol-2-yl)methanol has been investigated for its anti-inflammatory properties. In vitro studies have demonstrated that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, suggesting its potential use in treating inflammatory diseases. These findings have sparked interest in exploring the compound's broader therapeutic applications beyond traditional benzodiazepine uses.

The synthesis of (1-methyl-1H-1,3-benzodiazol-2-yl)methanol is well-documented in the literature and involves several steps that can be optimized for large-scale production. Common synthetic routes include cyclization reactions and functional group manipulations to introduce the methanol substituent. Advances in synthetic chemistry have led to more efficient and environmentally friendly methods, making it feasible to produce this compound on a commercial scale.

Pharmacokinetic studies have provided valuable insights into the behavior of (1-methyl-1H-1,3-benzodiazol-2-yl)methanol in biological systems. These studies have shown that the compound exhibits good oral bioavailability and a favorable pharmacokinetic profile, which are crucial factors for its potential use as an oral medication. Additionally, preliminary toxicology assessments have indicated that the compound is well-tolerated at therapeutic doses, with no significant adverse effects observed.

Clinical trials are currently underway to evaluate the safety and efficacy of (1-methyl-1H-1,3-benzodiazol-2-yl)methanol in various medical conditions. Early results from phase I trials have been promising, with the compound demonstrating a favorable safety profile and preliminary evidence of therapeutic benefit. These findings have paved the way for further clinical investigations to explore its potential as a new treatment option.

In conclusion, (1-methyl-1H-1,3-benzodiazol-2-yl)methanol (CAS No. 7467-35-8) is a promising compound with a wide range of potential applications in medicinal chemistry. Its unique chemical structure and biological activities make it an attractive candidate for further research and development. As ongoing studies continue to uncover new insights into its properties and mechanisms of action, this compound holds significant promise for advancing therapeutic options in various medical fields.

• 20572-01-4(1-Methyl-1H-benzimidazole-2-carboxylic Acid)
• 332899-55-5((1-propyl-1H-1,3-benzodiazol-2-yl)methanol)
• 155221-51-5(1H-Benzimidazole-2-methanol,1,6-dimethyl-)
• 331949-55-4((6-Chloro-1-methyl-1H-benzo[d]imidazol-2-yl)methanol)
• 215512-70-2(Methanediol,1-(1-ethenyl-1H-benzimidazol-2-yl)-)
• 27243-71-6(Hydroxylamine,O-[(1-methyl-1H-benzimidazol-2-yl)methyl]-, hydrochloride (1:2))
• 330472-50-9(1H-Benzimidazole-2-methanol,5-amino-1-methyl-)
• 380177-22-0((5-chloro-1-methyl-1H-1,3-benzodiazol-2-yl)methanol)
• 27243-70-5(1H-Benzimidazole,2-(ethoxymethyl)-1-methyl-)
• 102000-86-2(1-Benzimidazoleethanol,2-(hydroxymethyl)-(6CI))